Publications 2024

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
NPJ Breast Cancer, 10 (1), 30
DOI 10.1038/s41523-024-00638-2, PubMed 38653982

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Sharma A, Debik J, Naume B, Ohnstad HO, Oslo Breast Cancer Consortium (OSBREAC), Bathen TF, Giskeødegård GF (2024)
Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes
Oncogenesis, 13 (1), 22
DOI 10.1038/s41389-024-00521-6, PubMed 38871719

Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13760, PubMed 39545921

Vandraas K, Reinertsen KV, Gudim HB, Bowen CA, Gjerdalen G, Schlichting E, Naume B, Sætersdal A (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (12)
DOI 10.4045/tidsskr.24.0182, PubMed 39404245

Publications 2023

Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE (2023)
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Breast Cancer Res Treat, 204 (2), 249-259
DOI 10.1007/s10549-023-07147-z, PubMed 38123789

Vandraas KF, Smedsland S, Engan HK, Kiserud C, Naume B, Brekke M, Reinertsen KV (2023)
Late effects after breast cancer treatment
Tidsskr Nor Laegeforen, 143 (11)
DOI 10.4045/tidsskr.23.0017, PubMed 37589367

Publications 2022

Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B (2022)
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J (2022)
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
NPJ Breast Cancer, 8 (1), 94
DOI 10.1038/s41523-022-00465-3, PubMed 35974007

Publications 2021

Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M et al. (2021)
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
Eur J Cancer, 154, 128-137
DOI 10.1016/j.ejca.2021.06.028, PubMed 34265505

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, Naume B, Wiedswang G (2021)
Preoperative CTC-Detection by CellSearch^® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030485, PubMed 33513877

Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016

Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, Osbreac OBO, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2021)
Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
Cancers (Basel), 13 (23)
DOI 10.3390/cancers13236118, PubMed 34885228

Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J, Johnson J, Russnes HG, Bravo-Cordero JJ, Birbrair A, Naume B, Azhar M, Frenette PS, Aguirre-Ghiso JA (2021)
Bone marrow NG2⁺/Nestin⁺ mesenchymal stem cells drive DTC dormancy via TGFβ2
Nat Cancer, 2 (3), 327-339
DOI 10.1038/s43018-021-00179-8, PubMed 34993493

Publications 2020

Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H (2020)
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Mol Oncol, 15 (4), 957-967
DOI 10.1002/1878-0261.12865, PubMed 33252186

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Bendigtsen Schirmer C, Renolen A, Borgen E, Naume B, Wiedswang G (2020)
Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information
BMC Cancer, 20 (1), 1107
DOI 10.1186/s12885-020-07510-z, PubMed 33198661

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G (2020)
Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma
Ann Surg, 271 (3), 549-558
DOI 10.1097/SLA.0000000000003035, PubMed 30216219

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Kyte JA, Røssevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B (2020)
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer, 20 (1), 488
DOI 10.1186/s12885-020-06979-y, PubMed 32473650

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Naume B, Nygård JF (2019)
Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry
Int J Med Inform, 125, 102-109
DOI 10.1016/j.ijmedinf.2019.03.004, PubMed 30914174

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, Skaaheim Haug E, Naume B, Møller B (2019)
Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
Cancer Epidemiol, 61, 59-69
DOI 10.1016/j.canep.2019.05.004, PubMed 31153048

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W et al. (2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
J Natl Cancer Inst, 110 (6), 560-567
DOI 10.1093/jnci/djy018, PubMed 29659933

Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B (2018)
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Breast Cancer Res, 20 (1), 120
DOI 10.1186/s13058-018-1049-0, PubMed 30322396

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794

Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556

Publications 2017

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
DOI 10.1186/s13058-017-0812-y, PubMed 28356166

Bjørklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnæs GIG, Toppmeyer D, Riis M, Naume B, Børresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G (2017)
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
Sci Rep, 7 (1), 5568
DOI 10.1038/s41598-017-05537-0, PubMed 28717182

Broughton MN, Westgaard A, Paus E, Øijordsbakken M, Henanger KJ, Naume B, Bjøro T (2017)
Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
Tumour Biol, 39 (6), 1010428317707436
DOI 10.1177/1010428317707436, PubMed 28653892

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137
DOI 10.1007/s10549-016-4096-1, PubMed 28058579

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866

Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat Commun, 8 (1), 1379
DOI 10.1038/s41467-017-00510-x, PubMed 29123100

Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA (2017)
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
J Natl Cancer Inst, 109 (8)
DOI 10.1093/jnci/djw331, PubMed 28376188

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Breast Cancer Res, 19 (1), 125
DOI 10.1186/s13058-017-0916-4, PubMed 29183390

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653

Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G (2017)
Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
Ann Surg Oncol, 24 (8), 2113-2121
DOI 10.1245/s10434-017-5818-2, PubMed 28258416

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Publications 2016

Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B (2016)
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
Genome Biol, 17 (1), 250
DOI 10.1186/s13059-016-1109-7, PubMed 27931250

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P (2016)
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
Ann Oncol, 27 (9), 1719-25
DOI 10.1093/annonc/mdw249, PubMed 27358383

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE (2016)
Fatigue During and After Breast Cancer Therapy-A Prospective Study
J Pain Symptom Manage, 53 (3), 551-560
DOI 10.1016/j.jpainsymman.2016.09.011, PubMed 28042070

Publications 2015

Bjørklund SS, Kristensen VN, Seiler M, Kumar S, Alnæs GI, Ming Y, Kerrigan J, Naume B, Sachidanandam R, Bhanot G, Børresen-Dale AL, Ganesan S (2015)
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
BMC Cancer, 15, 524
DOI 10.1186/s12885-015-1510-8, PubMed 26183823

Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjørnbeth BA, Borgen E, Naume B, Waage A, Wiedswang G (2015)
Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases
Ann Surg Oncol, 22 (12), 4029-37
DOI 10.1245/s10434-015-4482-7, PubMed 25801354

Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
Mol Oncol, 10 (1), 59-72
DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095

Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015)
Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival
Ann Surg, 261 (1), 164-71
DOI 10.1097/SLA.0000000000000580, PubMed 24509211

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
PLoS One, 10 (10), e0139965
DOI 10.1371/journal.pone.0139965, PubMed 26460974

Publications 2014

Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014)
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
Breast Cancer Res Treat, 145 (2), 411-8
DOI 10.1007/s10549-014-2939-1, PubMed 24728613

Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Børresen-Dale AL, Kristensen VN, Tost J (2014)
Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients
Int J Cancer, 134 (11), 2615-25
DOI 10.1002/ijc.28606, PubMed 24395279

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
Genome Biol, 15 (8), 435
DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004

Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B (2014)
Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
BMC Cancer, 14, 514
DOI 10.1186/1471-2407-14-514, PubMed 25023626

Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J et al. (2014)
International study on inter-reader variability for circulating tumor cells in breast cancer
Breast Cancer Res, 16 (2), R43
DOI 10.1186/bcr3647, PubMed 24758318

Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
Clin Cancer Res, 21 (5), 1207-14
DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
J Clin Oncol, 32 (34), 3848-57
DOI 10.1200/JCO.2014.56.9327, PubMed 25366688

Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Børresen-Dale AL, Hackermüller J, Baumbusch LO (2014)
Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes
PLoS One, 9 (9), e106076
DOI 10.1371/journal.pone.0106076, PubMed 25264628

Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG (2014)
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
Genes Chromosomes Cancer, 54 (4), 235-48
DOI 10.1002/gcc.22237, PubMed 25546585

Publications 2013

Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
PLoS One, 8 (1), e53014
DOI 10.1371/journal.pone.0053014, PubMed 23382830

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
The clinical impact of mean vessel size and solidity in breast carcinoma patients
PLoS One, 8 (10), e75954
DOI 10.1371/journal.pone.0075954, PubMed 24146798

Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN (2013)
Next-generation sequencing of disseminated tumor cells
Front Oncol, 3, 320
DOI 10.3389/fonc.2013.00320, PubMed 24427740

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B (2013)
Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
Breast Cancer Res Treat, 138 (2), 485-97
DOI 10.1007/s10549-013-2439-8, PubMed 23456230

Publications 2012

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
Histopathology, 61 (3), 350-64
DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
Histol Histopathol, 27 (10), 1315-25
DOI 10.14670/HH-27.1315, PubMed 22936450

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
DOI 10.5402/2012/176789, PubMed 22666610

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Molloy TJ, Roepman P, Naume B, van't Veer LJ (2012)
A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients
PLoS One, 7 (2), e32426
DOI 10.1371/journal.pone.0032426, PubMed 22384245

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Publications 2011

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis
Clin Cancer Res, 17 (9), 2967-76
DOI 10.1158/1078-0432.CCR-10-2515, PubMed 21415211

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
Proc Natl Acad Sci U S A, 109 (8), 2802-7
DOI 10.1073/pnas.1108781108, PubMed 21908711

Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2011)
High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
Int J Cancer, 131 (4), E405-15
DOI 10.1002/ijc.26444, PubMed 21935921

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237

Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC (2011)
Combining gene signatures improves prediction of breast cancer survival
PLoS One, 6 (3), e17845
DOI 10.1371/journal.pone.0017845, PubMed 21423775

Publications 2010

Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2010)
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
Breast Cancer Res Treat, 125 (3), 729-38
DOI 10.1007/s10549-010-0911-2, PubMed 20449649

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2010)
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
Eur Radiol, 21 (6), 1188-99
DOI 10.1007/s00330-010-2020-3, PubMed 21127880

Fu YP, Edvardsen H, Kaushiva A, Arhancet JP, Howe TM, Kohaar I, Porter-Gill P, Shah A, Landmark-Høyvik H, Fosså SD, Ambs S, Naume B, Børresen-Dale AL, Kristensen VN, Prokunina-Olsson L (2010)
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations
Mol Cancer, 9, 113
DOI 10.1186/1476-4598-9-113, PubMed 20482849

Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB (2010)
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables
Mol Oncol, 5 (1), 77-92
DOI 10.1016/j.molonc.2010.11.002, PubMed 21169070

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003

Nesvold IL, Fosså SD, Holm I, Naume B, Dahl AA (2010)
Arm/shoulder problems in breast cancer survivors are associated with reduced health and poorer physical quality of life
Acta Oncol, 49 (3), 347-53
DOI 10.3109/02841860903302905, PubMed 19842790

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL (2010)
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421

Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Børresen-Dale AL, Tost J, Kristensen V (2010)
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer
Mol Oncol, 5 (1), 61-76
DOI 10.1016/j.molonc.2010.11.004, PubMed 21212030

Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P (2010)
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
J Clin Oncol, 28 (27), 4129-34
DOI 10.1200/JCO.2009.26.4200, PubMed 20713855

Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN (2010)
Allele-specific copy number analysis of tumors
Proc Natl Acad Sci U S A, 107 (39), 16910-5
DOI 10.1073/pnas.1009843107, PubMed 20837533

Publications 2009

Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM (2009)
Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count
Histol Histopathol, 24 (8), 1049-59
DOI 10.14670/HH-24.1049, PubMed 19554512

Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S (2009)
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide
Clin Cancer Res, 15 (12), 4165-73
DOI 10.1158/1078-0432.CCR-09-0119, PubMed 19509150

Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
Nucleic Acids Res, 37 (12), e89
DOI 10.1093/nar/gkp413, PubMed 19474344

Park D, Kåresen R, Naume B, Synnestvedt M, Beraki E, Sauer T (2009)
The prognostic impact of occult nodal metastasis in early breast carcinoma
Breast Cancer Res Treat, 118 (1), 57-66
DOI 10.1007/s10549-009-0340-2, PubMed 19219629

Wist EA, Naume B (2009)
Brystkreft
In Medikamentell kreftbehandling, Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo, 357-362
PublikaID 79, ISBN 978-829923312-5

Publications 2008

Baumbusch LO, Aarøe J, Johansen FE, Hicks J, Sun H, Bruhn L, Gunderson K, Naume B, Kristensen VN, Liestøl K, Børresen-Dale AL, Lingjaerde OC (2008)
Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors
BMC Genomics, 9, 379
DOI 10.1186/1471-2164-9-379, PubMed 18691401

Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL (2008)
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM (2008)
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination
Clin Cancer Res, 14 (8), 2341-50
DOI 10.1158/1078-0432.CCR-07-4214, PubMed 18413823

Nesvold IL, Fosså SD, Naume B, Dahl AA (2008)
Kwan's arm problem scale: psychometric examination in a sample of stage II breast cancer survivors
Breast Cancer Res Treat, 117 (2), 281-8
DOI 10.1007/s10549-008-0288-7, PubMed 19112616

Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvänen AC, Naume B, Børresen-Dale AL, Kristensen VN (2008)
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients
Genes Chromosomes Cancer, 47 (8), 680-96
DOI 10.1002/gcc.20569, PubMed 18398821

Publications 2007

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292

Nordgard SH, Johansen FE, Alnaes GI, Naume B, Børresen-Dale AL, Kristensen VN (2007)
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes
Breast Cancer Res, 9 (6), 113
DOI 10.1186/bcr1784, PubMed 18036273

Wiedswang G, Naume B (2007)
Can detection of circulating tumor cells in peripheral blood provide prognostic data in breast cancer?
Nat Clin Pract Oncol, 4 (3), 154-5
DOI 10.1038/ncponc0742, PubMed 17290243

Publications 2006

Borgen E, Pantel K, Schlimok G, Müller P, Otte M, Renolen A, Ehnle S, Coith C, Nesland JM, Naume B (2006)
A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow
Cytometry B Clin Cytom, 70 (6), 400-9
DOI 10.1002/cyto.b.20114, PubMed 16924637

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E (2006)
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation
Cancer, 107 (5), 885-92
DOI 10.1002/cncr.22076, PubMed 16874814

Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, Yoon S, Wigler M, Ye K, Børresen-Dale AL, Naume B, Schlicting E, Norton L, Hägerström T, Skoog L, Auer G, Månér S, Lundin P, Zetterberg A (2006)
Novel patterns of genome rearrangement and their association with survival in breast cancer
Genome Res, 16 (12), 1465-79
DOI 10.1101/gr.5460106, PubMed 17142309

Muggerud AA, Johnsen H, Barnes DA, Steel A, Lønning PE, Naume B, Sørlie T, Børresen-Dale AL (2006)
Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes
BMC Cancer, 6, 59
DOI 10.1186/1471-2407-6-59, PubMed 16536878

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL (2006)
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms
BMC Genomics, 7, 127
DOI 10.1186/1471-2164-7-127, PubMed 16729877

Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, Naume B (2006)
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer
Int J Cancer, 118 (8), 2013-9
DOI 10.1002/ijc.21576, PubMed 16287086

Publications 2005

Braun S, Naume B (2005)
Circulating and disseminated tumor cells
J Clin Oncol, 23 (8), 1623-6
DOI 10.1200/JCO.2005.10.073, PubMed 15755968

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer
N Engl J Med, 353 (8), 793-802
DOI 10.1056/NEJMoa050434, PubMed 16120859

Publications 2004

Naume B, Borgen E, Tøssvik S, Pavlak N, Oates D, Nesland JM (2004)
Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method
Cytotherapy, 6 (3), 244-52
DOI 10.1080/14653240410006086, PubMed 15203981

Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Quist H, Janbu J, Harbitz TB, Nesland JM (2004)
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells
In Clinical cancer research, AACR Publications Department, Philadelphia, PA, 10(2004)9, S. 3091-7
BIBSYS 05181322x

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004)
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells
Clin Cancer Res, 10 (9), 3091-7
DOI 10.1158/1078-0432.ccr-03-0373, PubMed 15131048

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004)
Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome
Clin Cancer Res, 10 (16), 5342-8
DOI 10.1158/1078-0432.CCR-04-0245, PubMed 15328170

Publications 2003

Wiedswang G, Borgen E, Karesen R, Naume B (2003)
Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed
Cytotherapy, 5 (1), 40-5
DOI 10.1080/14653240310000065, PubMed 12745581

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003)
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer
J Clin Oncol, 21 (18), 3469-78
DOI 10.1200/JCO.2003.02.009, PubMed 12972522

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist HL, Schlichting E, Sauer T, Janbu J, Harbitz TB, Naume B (2003)
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer
In Journal of clinical oncology, The Society, Alexandria VA, 21(2003)18, s.3469-78
BIBSYS 041728920

Publications 2001

Borgen E, Naume B, Nesland JM, Nowels KW, Pavlak N, Ravkin I, Goldbard S (2001)
Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples
Cytometry, 46 (4), 215-21
DOI 10.1002/cyto.1130, PubMed 11514954

Naume B, Borgen E, Kvalheim G, Kåresen R, Qvist H, Sauer T, Kumar T, Nesland JM (2001)
Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics
Clin Cancer Res, 7 (12), 4122-9
PubMed 11751511

Wiedswang G, Naess AB, Naume B, Kåresen R (2001)
Micrometastasis to axillary lymph nodes and bone marrow in breast cancer patients
Breast, 10 (3), 237-42
DOI 10.1054/brst.2000.0245, PubMed 14965591

Publications 1999

Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K (1999)
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells
Cytotherapy, 1 (5), 377-88
DOI 10.1080/0032472031000141283, PubMed 20426539

Kvalheim G, Naume B, Nesland JM (1999)
Minimal residual disease in breast cancer
Cancer Metastasis Rev, 18 (1), 101-8
DOI 10.1023/a:1006216504892, PubMed 10505549

Publications 1998

Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B (1998)
Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
J Pathol, 185 (4), 427-34
DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7, PubMed 9828843

Naume B (1998)
[New methods for early detection of breast cancer metastasis]
Tidsskr Nor Laegeforen, 118 (3), 354
PubMed 9499719

Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, Ravnås G, Qvist H, Kåresen R, Kvalheim G (1998)
Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
Int J Cancer, 78 (5), 556-60
DOI 10.1002/(sici)1097-0215(19981123)78:5<556::aid-ijc5>3.0.co;2-g, PubMed 9808522

Publications 1997

Naume B, Borgen E, Beiske K, Herstad TK, Ravnås G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G (1997)
Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
J Hematother, 6 (2), 103-14
DOI 10.1089/scd.1.1997.6.103, PubMed 9131439

Publications 1995

Fosså SD, Aamdal S, Naume B, Gallati H (1995)
Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy
Acta Oncol, 34 (5), 599-603
DOI 10.3109/02841869509094034, PubMed 7546824

Publications 1994

Naume B, Espevik T (1994)
Immunoregulatory effects of cytokines on natural killer cells
Scand J Immunol, 40 (2), 128-34
DOI 10.1111/j.1365-3083.1994.tb03441.x, PubMed 8047834

Publications 1993

Borset M, Helseth E, Naume B, Waage A (1993)
Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation
Br J Haematol, 85 (3), 446-51
DOI 10.1111/j.1365-2141.1993.tb03331.x, PubMed 8136264

Naume B (1993)
Immunoregulatory effects of cytokines on NK cells
In Acta Universitatis Nidrosiensis Facultatis Medicinae, Series A, Dissertations, Tapir, [Trondheim], 84, 1 b. (flere pag.)
BIBSYS 931997518, ISBN 82-519-1473-6

Naume B, Gately MK, Desai BB, Sundan A, Espevik T (1993)
Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation
Cytokine, 5 (1), 38-46
DOI 10.1016/1043-4666(93)90022-w, PubMed 8097934

Naume B, Johnsen AC, Espevik T, Sundan A (1993)
Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12
Eur J Immunol, 23 (8), 1831-8
DOI 10.1002/eji.1830230815, PubMed 7688307

Publications 1992

Naume B, Gately M, Espevik T (1992)
A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells
J Immunol, 148 (8), 2429-36
PubMed 1373169

Publications 1991

Naume B, Espevik T (1991)
Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study
J Immunol, 147 (7), 2208-14
PubMed 1717551

Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T (1991)
Immunomagnetic isolation of NK and LAK cells
J Immunol Methods, 136 (1), 1-9
DOI 10.1016/0022-1759(91)90242-8, PubMed 1704900

Naume B, Shalaby R, Lesslauer W, Espevik T (1991)
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells
J Immunol, 146 (9), 3045-8
PubMed 1707931